Press Releases Armata Pharmaceuticals, Inc.

Equities

ARMP

US04216R1023

Market Closed - Nyse Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
3.15 ^USD	+5.00%		+17.98%	-2.78%

Jul. 11	Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa Infection	CI
May. 07	Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection	Jul. 12	AQ
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024	Jul. 11	AQ
Armata Pharmaceuticals : Shareholder Meeting - Form 8-K	Mar. 22	PU
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update	Nov. 15	AQ
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus	23-09-27	AQ
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference	23-09-22	AQ
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update	23-08-15	AQ
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics	23-07-12	AQ
Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy	23-06-01	AQ
Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update	23-05-12	AQ
ARMATA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-12	AQ
ARMATA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	23-05-05	AQ
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update	23-03-17	AQ
ARMATA PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-16	AQ
ARMATA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-03-16	AQ
ARMATA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-03-06	AQ
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC	23-01-11	AQ
Armata Pharmaceuticals : Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC - Form 8-K	23-01-10	PU
ARMATA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	23-01-10	AQ
ARMATA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	22-12-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Armata Pharmaceuticals, Inc.

Equities

ARMP

US04216R1023

Press Releases

Filters